Liquidia Q4 Earnings Call Highlights

Liquidia (NASDAQ: LQDA) executives highlighted a rapid commercial ramp for YUTREPIA, expanding clinical plans for both YUTREPIA and the next-generation candidate L-606, and improving profitability during the company's full year 2025 financial results and corporate update call. Commercial launch metrics and prescribing trends Chief Executive Officer Dr. Roger Jeffs said 2025 demonstrated Liquidia's ability to "launch,